Keen Eye Technologies

Keen Eye Technologies is an AI platform company in the biotechnology and healthcare industries, with a focus on elevating pathology for drug development and diagnostics. Their slogan, "AI platform elevates pathology for drug development and diagnostics, supporting all stages and organ classes," captures the essence of their mission. Founded in 2015, the company received a €6.00M Series A investment on 29 April 2019 from CM-CIC Capital Finance. As an AI platform provider, Keen Eye Technologies plays a crucial role in enhancing computational pathology to facilitate superior drug development and diagnostics. They cover the entire spectrum of drug development, from preclinical phases to clinical assay development. Their technology is adaptable and agile, catering to tissue samples from any organ class and therapeutic area. This recent investment signifies a vote of confidence in the potential of Keen Eye Technologies, and it positions the company for further growth and innovation in the field of AI-powered pathology for drug development and diagnostics.